Peripheral Neuropathy Treatment Market, by Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), by Treatment (Pharmacological Therapies (Pain Relievers, Anti-seizure Medications,

Peripheral Neuropathy Treatment Market, by Type (Diabetic Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy, Idiopathic Peripheral Neuropathy, and Others), by Treatment (Pharmacological Therapies (Pain Relievers, Anti-seizure Medications, and Antidepressants) and Non-pharmacological Therapies (Transcutaneous Electrical Nerve Stimulation, Plasma Exchange and Intravenous Immune Globulin, and Others), by Distribution Channel (Hospitals and Clinics, Ambulatory Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Peripheral neuropathy is a disorder that affects the peripheral nerves. Peripheral neuropathy has a variety of systemic, metabolic, and toxic causes, for instance diabetes in metabolic cause. The most common treatable causes include diabetes mellitus, hypothyroidism, and nutritional deficiencies. The diagnosis require careful clinical assessment, judicious laboratory testing, and electro diagnostic studies or nerve biopsy, if the diagnosis remains unclear.
Market Dynamics
Rising aging population is expected to drive the global peripheral neuropathy treatment market growth. For instance, according to an article published by the World Health Organization (WHO) in February 2018, reports that between 2015 and 2050, the proportion of the worldwide geriatric population will nearly double from 12% to 22%.
Moreover, rising diabetic cases is expected to drive the market growth. For instance, according to an article published by the International Diabetes Federation (IDF), in 2017, the estimated number of 18 to 99 year old diabetic patients was around 425 million globally.
researched
medicinal properties of cannabis and its derivatives are widely
Researched
Medicinal properties of cannabis and its derivatives are widely
researched
medicinal properties of cannabis and its derivatives are widely
researched
medicinal properties of cannabis and its derivatives are widely
researched
Key features of the study:
This report provides in-depth analysis of the global peripheral neuropathy treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global peripheral neuropathy treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddy's Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd, among others.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
The global peripheral neuropathy treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global peripheral neuropathy treatment market.
Detailed Segmentation:
Global Peripheral Neuropathy Treatment Market, By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
Global Peripheral Neuropathy Treatment Market, By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
Global Peripheral Neuropathy Treatment Market, By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
Global Peripheral Neuropathy Treatment Market, By Region:
North America
By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
By Country:
U.S.
Canada
Latin America
By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
By Treatment:
By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
By Country:
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type:
Diabetic Peripheral Neuropathy
Chemotherapy-induced Peripheral Neuropathy
Idiopathic Peripheral Neuropathy
Others
By Treatment:
Pharmacological Therapies
Pain Relievers
Anti-seizure Medications
Antidepressants
Non-pharmacological Therapies
Transcutaneous Electrical Nerve Stimulation
Plasma Exchange and Intravenous Immune Globulin
Others
By Distribution Channel:
Hospitals and Clinics
Ambulatory Centers
Others
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Abbott*
Company Overview
Product Portfolio
Financial Performance
Key Highlights
Market Strategies
Bristol Myers Squibb
Cipla Limited
Eli Lilly and Company
GlaxoSmithKline plc.
Lupin Limited
Merck and Co. Inc.
Novartis AG
Pfizer Inc.
Dr. Reddy's Laboratories
Mylan NV
Johnson & Johnson Services Inc.
Teva Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.